Kun Tang

4.6k total citations
129 papers, 3.0k citations indexed

About

Kun Tang is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Cancer Research. According to data from OpenAlex, Kun Tang has authored 129 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 51 papers in Pulmonary and Respiratory Medicine, 35 papers in Molecular Biology and 26 papers in Cancer Research. Recurrent topics in Kun Tang's work include Cancer-related molecular mechanisms research (17 papers), MicroRNA in disease regulation (15 papers) and Nanoplatforms for cancer theranostics (13 papers). Kun Tang is often cited by papers focused on Cancer-related molecular mechanisms research (17 papers), MicroRNA in disease regulation (15 papers) and Nanoplatforms for cancer theranostics (13 papers). Kun Tang collaborates with scholars based in China, United States and Australia. Kun Tang's co-authors include Zhangqun Ye, Hua Xu, Zhiqiang Chen, Haibing Xiao, Xia Ding, Heng Li, Haoran Liu, Yu Gan, Kehua Jiang and Xiaoqi Yang and has published in prestigious journals such as SHILAP Revista de lepidopterología, ACS Nano and PLoS ONE.

In The Last Decade

Kun Tang

118 papers receiving 3.0k citations

Peers

Kun Tang

PRM

SURGE

ONCOL

Bin Zhao China

Linda Sugar Canada

Zhangqun Ye China

Won Tae Kim South Korea

Jinbo Chen China

Ning Zhang China

Bin Sun China

Joseph Wagner United States

Kai Cui China

Wenqi Wu China

Bin Zhao China

Kun Tang

1.6k ×1.1

895 ×0.8

800 ×0.9

PRM

457 ×1.0

SURGE

506 ×1.6

ONCOL

Citations per year, relative to Kun Tang Kun Tang (= 1×) peers Bin Zhao

Countries citing papers authored by Kun Tang

Since Specialization

Citations

This map shows the geographic impact of Kun Tang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kun Tang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kun Tang more than expected).

Fields of papers citing papers by Kun Tang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kun Tang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kun Tang. The network helps show where Kun Tang may publish in the future.

Co-authorship network of co-authors of Kun Tang

This figure shows the co-authorship network connecting the top 25 collaborators of Kun Tang. A scholar is included among the top collaborators of Kun Tang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kun Tang. Kun Tang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wu, Jian, et al.. (2025). Genetically engineered hybrid membrane-coated nanoparticles enable triple activation of dendritic cells for synergistic bladder cancer immunotherapy. Chemical Engineering Journal. 510. 161652–161652.

Wu, Jian, Qiu Huang, Yu He, et al.. (2025). METTL3 promotes an immunosuppressive microenvironment in bladder cancer via m6A-dependent CXCL5/CCL5 regulation. Journal for ImmunoTherapy of Cancer. 13(4). e011108–e011108. 2 indexed citations

Liu, Yutong, et al.. (2025). Comprehensive Characterization of Aroma Compounds in Four Different Varieties of Cigar Tobacco Leaves from China Using HS-SPME-GC × GC-TOF-MS Combined with Flavor Profiling. ACS Omega. 10(6). 5819–5828.

Liu, Hongming, Xiaolong Chen, Zhen Wang, et al.. (2025). Reprogramming of Glucose Metabolism by Nanocarriers to Improve Cancer Immunotherapy: Recent Advances and Applications. International Journal of Nanomedicine. Volume 20. 4201–4234. 3 indexed citations

Geng, Rui, et al.. (2025). ROS-responsive resiquimod prodrug nanoparticles for macrophage reprogramming and enhanced immune checkpoint inhibitor therapy in bladder cancer. Biomaterials. 326. 123677–123677.

Tang, Kun, et al.. (2025). A review of laser-assisted cutting of hard and brittle materials: Tools, devices and mechanisms. Optics & Laser Technology. 189. 113105–113105.

Gao, Pengfei, Yanjiao Lu, Kun Tang, et al.. (2024). Ficolin-1 ameliorates pulmonary fibrosis via directly binding to TGF-β1. Journal of Translational Medicine. 22(1). 1051–1051. 1 indexed citations

Tao, Ye, Yu He, Wen Deng, et al.. (2024). Recent Advances in Nanomaterials for the Treatment of Acute Kidney Injury. ACS Applied Materials & Interfaces. 16(10). 12117–12148. 15 indexed citations

Wang, Qing, et al.. (2024). Nanoparticles targeting the adenosine pathway for cancer immunotherapy. Journal of Materials Chemistry B. 12(24). 5787–5811. 3 indexed citations

10.

Ge, Yue, Yu He, Xiao Liu, et al.. (2024). The Application of Nanoparticles Targeting Cancer-Associated Fibroblasts. International Journal of Nanomedicine. Volume 19. 3333–3365. 15 indexed citations

11.

Deng, Wen, et al.. (2024). Cell membrane coated nanoparticles as a biomimetic drug delivery platform for enhancing cancer immunotherapy. Nanoscale. 16(18). 8708–8738. 12 indexed citations

12.

Wu, Jian, et al.. (2023). Antioxidant nanozymes in kidney injury: mechanism and application. Nanoscale. 15(32). 13148–13171. 16 indexed citations

13.

Wu, Jian, Xiao Liu, Yu He, et al.. (2022). Second near-infrared nanomaterials for cancer photothermal immunotherapy. Materials Today Advances. 17. 100339–100339. 13 indexed citations

14.

Liu, Xiao, Xia Ding, Ejun Peng, et al.. (2021). Circular RNAs in prostate cancer: Biogenesis, biological functions, and clinical significance. Molecular Therapy — Nucleic Acids. 26. 1130–1147. 24 indexed citations

15.

Liu, Xiao, Xia Ding, Ejun Peng, et al.. (2021). Comparison of two techniques for the management of 2–3 cm lower pole renal calculi in obese patients. World Journal of Urology. 40(2). 513–518. 14 indexed citations

16.

Yang, Xiaoqi, Tao Ye, Haoran Liu, et al.. (2021). Expression profiles, biological functions and clinical significance of circRNAs in bladder cancer. Molecular Cancer. 20(1). 4–4. 130 indexed citations

17.

Ding, Xia, Ejun Peng, Xiaoqi Yang, et al.. (2021). Comparison of contrast-enhanced ultrasound versus conventional ultrasound-guided percutaneous nephrolithotomy in patients with nondilated collecting system: a randomized controlled trial. European Radiology. 31(9). 6736–6746. 8 indexed citations

18.

Zhang, Lei, Wen Liu, Fangyan Liu, et al.. (2020). IMCA Induces Ferroptosis Mediated by SLC7A11 through the AMPK/mTOR Pathway in Colorectal Cancer. Oxidative Medicine and Cellular Longevity. 2020. 1–14. 118 indexed citations

19.

Liu, Haoran, Tao Ye, Xiaoqi Yang, et al.. (2020). Predictive and Prognostic Role of PD-L1 in Urothelial Carcinoma Patients with Anti-PD-1/PD-L1 Therapy: A Systematic Review and Meta-Analysis. Disease Markers. 2020. 1–16. 15 indexed citations

20.

Gan, Yu, Weimin Yao, Kiranmai Gumireddy, et al.. (2014). Pseudogene PTENP1 Functions as a Competing Endogenous RNA to Suppress Clear-Cell Renal Cell Carcinoma Progression. Molecular Cancer Therapeutics. 13(12). 3086–3097. 166 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact